MARKET

KURA

KURA

Kura Oncology
NASDAQ

Real-time Quotes | Nasdaq Last Sale

29.86
-0.12
-0.40%
After Hours: 29.90 +0.04 +0.13% 16:00 03/03 EST
OPEN
29.95
PREV CLOSE
29.98
HIGH
30.29
LOW
28.97
VOLUME
1.22M
TURNOVER
--
52 WEEK HIGH
43.00
52 WEEK LOW
6.35
MARKET CAP
1.98B
P/E (TTM)
-17.7095
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Mitogen Activated Protein Kinase 9 Market Global Growth, New Updates 2021 Overview, Industry Expansion, Opportunities, Market by Type, Size, Share, by Manufacturers, Regional Analysis & Forecast by 2025
Mar 01, 2021 (The Expresswire) -- Global “Mitogen Activated Protein Kinase 9 Market” report presents an in-depth analysis of market development. The report...
The Express Wire · 2d ago
Analysts Offer Insights on Healthcare Companies: Kura Oncology (KURA) and Lantheus (LNTH)
SmarterAnalyst · 5d ago
--Analyst Actions: SVB Leerink Adjusts Price Target on Kura Oncology to $40 From $42, Maintains Outperform Rating
MT Newswires · 5d ago
--Analyst Actions: Wedbush Adjusts Kura Oncology's Price Target to $53 From $56, Keeps Outperform Rating
MT Newswires · 6d ago
8-K: Kura Oncology, Inc.
(EDGAR Online via COMTEX) -- false 0001422143 0001422143 2021-02-24 2021-02-24 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 6d ago
DJ Kura Oncology, Inc. CEO Troy Wilson on Q4 2020 Results -- Earnings Call Transcript >KURA
Dow Jones · 02/24 18:52
FSR, SUNW, OSTK and DKL among midday movers
Gainers: Sypris Solutions (SYPR) +83%.9F (JFU) +39%.Owens & Minor (OMI) +38%.Sunworks (SUNW) +34%.R. R. Donnelley & Sons (RRD) +30%.Fisker (FSR) +28%.PubMatic (PUBM) +27%.dMY Technology (DMYI) +26%.Timber Pharmaceuticals (TMBR) +25%.Cancer Genetics (CGIX) ...
Seekingalpha · 02/24 17:49
DJ Kura Oncology Price Target Cut to $43.00/Share From $45.00 by HC Wainwright & Co.
Dow Jones · 02/24 16:12
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of KURA. Analyze the recent business situations of Kura Oncology through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average KURA stock price target is 43.67 with a high estimate of 60.00 and a low estimate of 30.00.
EPS
Institutional Holdings
Institutions: 260
Institutional Holdings: 66.85M
% Owned: 100.97%
Shares Outstanding: 66.21M
TypeInstitutionsShares
Increased
76
13.58M
New
65
5.05M
Decreased
54
6.75M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-3.96%
Pharmaceuticals & Medical Research
-1.89%
Key Executives
Chairman/President/Chief Executive Officer/Director
Troy Wilson
Chief Financial Officer
Marc Grasso
Chief Operating Officer
Kathleen Ford
Other
Stephen Dale
Chief Compliance Officer/Secretary
Obsolete34418489538 Obsolete34418489538
Other
Kirsten Flowers
Other
Bridget Martell
Secretary
James Basta
Lead Director/Independent Director
faheem Hasnain
Lead Director/Independent Director
Faheem Hasnain
Independent Director
Robert Hoffman
Independent Director
Thomas Malley
Independent Director
Diane Parks
Independent Director
Steven Stein
Independent Director
Mary Szela
  • Dividends
  • Splits
  • Insider Activity
No Data
About KURA
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small molecule product candidates that targets cell-signaling pathways, which drives the progression of certain cancers. It is developing its lead product candidate, tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. It is advancing KO-947, a small molecule inhibitor of extracellular-signal-regulated kinase (ERK), as a treatment for patients with tumors that have mutations in or other dysregulation of the mitogen-activated protein kinase (MAPK), signaling pathway, including pancreatic cancer, colorectal cancer, non-small cell lung cancer (NSCLC) and melanoma.

Webull offers kinds of Kura Oncology Inc stock information, including NASDAQ:KURA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KURA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading KURA stock methods without spending real money on the virtual paper trading platform.